in Business

Merck Buying Drug Targeting B-Cell Diseases for Up to $1.3 Billion

551 Views

Merck Buying Drug Targeting B-Cell Diseases for Up to .3 Billion




Merck has struck a deal value as much as $1.3 billion to purchase an investigational drug focusing on B-cell related ailments.

Report

Comments

Express your views here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Disqus Shortname not set. Please check settings

Written by EGN NEWS DESK

Breaking Down the Cuckoo Ending of ‘Cuckoo’

Breaking Down the Cuckoo Ending of ‘Cuckoo’
Algonquin Power to Sell Renewable Energy Business for .5 Billion

Algonquin Power to Sell Renewable Energy Business for $2.5 Billion